Payment overview · 2025
General Payments
$984.03
45 reported records · 16 companies
Healthcare provider profile · identity verified
Tracy Hooper, FNP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · CHATSWORTH, GA · NPI 1619962206
Verified facts
What the public records show
CMS Open Payments records show Tracy Hooper, FNP received $984.03 in general payments during 2025 across 45 reported records.
Axsome Therapeutics, Inc. accounted for 15.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 24 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Gemtesa, Jardiance, Kerendia, Mounjaro, Ozempic, Rybelsus, Trelegy Ellipta, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 81 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Vraylar by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OTEZLA as an associated drug or biological on 177267 records involving 48600 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Otezla by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BEVESPI AEROSPHERE as an associated drug or biological on 763 records involving 473 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Bevespi Aerosphere by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 236 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Kerendia by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 172 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 122 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 424 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 163 claims for Eliquis by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $154.95 | 15.8% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $144.75 | 14.7% | 7 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $142.05 | 14.4% | 9 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $99.68 | 10.1% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $67.63 | 6.9% | 4 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $63.81 | 6.5% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $59.55 | 6.0% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $53.29 | 5.4% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $50.40 | 5.1% | 2 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $39.43 | 4.0% | 2 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $25.99 | 2.6% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $22.26 | 2.3% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $16.30 | 1.7% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $15.48 | 1.6% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $14.97 | 1.5% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $13.49 | 1.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $984.03 | 45 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $154.95 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $103.49 | 7 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $99.68 | 4 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $76.22 | 4 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $76.22 | 4 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $76.22 | 4 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $68.53 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $68.53 | 3 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $63.81 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $53.29 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $50.40 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $40.78 | 2 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $39.43 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $38.56 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $38.56 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $32.75 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $30.63 | 2 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $25.99 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $22.26 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $19.28 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $16.30 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $15.48 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $14.97 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $13.49 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 163 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 236 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 65 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 33 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 122 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 424 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 45 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 172 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 30 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
81 | 16 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
53 | 11 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | OTEZLA open payments reported associated product |
CMS Open Payments — General Payments 177267 supporting records · 48600 recipient NPIs · example record 1226871616 |
Otezla · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BEVESPI AEROSPHERE open payments reported associated product |
CMS Open Payments — General Payments 763 supporting records · 473 recipient NPIs · example record 1206131384 |
Bevespi Aerosphere · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
236 | 53 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
31 | 11 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
172 | 38 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
65 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
122 | 21 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
424 | 64 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
163 | 37 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 901 | 232 |
| Levothyroxine Sodium | Levothyroxine Sodium | 831 | 189 |
| Amlodipine Besylate | Amlodipine Besylate | 619 | 160 |
| Pantoprazole Sodium | Pantoprazole Sodium | 559 | 141 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 555 | 133 |
| Tramadol Hcl | Tramadol Hcl | 501 | 112 |
| Lisinopril | Lisinopril | 500 | 112 |
| Gabapentin | Gabapentin | 455 | 99 |
| Ozempic | Semaglutide | 424 | 64 |
| Omeprazole | Omeprazole | 405 | 102 |
| Metformin Hcl Er | Metformin Hcl | 333 | 82 |
| Montelukast Sodium | Montelukast Sodium | 333 | 89 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 293 | 80 |
| Losartan Potassium | Losartan Potassium | 286 | 72 |
| Sertraline Hcl | Sertraline Hcl | 280 | 68 |
| Famotidine | Famotidine | 276 | 67 |
| Tizanidine Hcl | Tizanidine Hcl | 239 | 43 |
| Farxiga | Dapagliflozin Propanediol | 236 | 53 |
| Furosemide | Furosemide | 235 | 63 |
| Tamsulosin Hcl | Tamsulosin Hcl | 235 | 65 |
| Buspirone Hcl | Buspirone Hcl | 224 | 51 |
| Metformin Hcl | Metformin Hcl | 191 | 52 |
| Metoprolol Succinate | Metoprolol Succinate | 191 | 50 |
| Potassium Chloride | Potassium Chloride | 191 | 50 |
| Pregabalin | Pregabalin | 191 | 37 |
| Hydrochlorothiazide | Hydrochlorothiazide | 188 | 49 |
| Metoprolol Tartrate | Metoprolol Tartrate | 186 | 56 |
| Alprazolam | Alprazolam | 183 | 22 |
| Trazodone Hcl | Trazodone Hcl | 182 | 53 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 172 | 38 |
| Fluticasone Propionate | Fluticasone Propionate | 170 | 52 |
| Ezetimibe | Ezetimibe | 165 | 51 |
| Eliquis | Apixaban | 163 | 37 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 163 | 44 |
| Alendronate Sodium | Alendronate Sodium | 144 | 30 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 141 | 30 |
| Clonazepam | Clonazepam | 135 | 23 |
| Duloxetine Hcl | Duloxetine Hcl | 132 | 35 |
| Allopurinol | Allopurinol | 131 | 33 |
| Pravastatin Sodium | Pravastatin Sodium | 126 | 27 |
| Escitalopram Oxalate | Escitalopram Oxalate | 122 | 32 |
| Mounjaro | Tirzepatide | 122 | 21 |
| Quetiapine Fumarate | Quetiapine Fumarate | 116 | 29 |
| Bupropion Xl | Bupropion Hcl | 113 | 33 |
| Carvedilol | Carvedilol | 108 | 32 |
| Amitriptyline Hcl | Amitriptyline Hcl | 105 | 16 |
| Meloxicam | Meloxicam | 103 | 30 |
| Tresiba Flextouch U-100 | Insulin Degludec | 100 | 17 |
| Citalopram Hbr | Citalopram Hydrobromide | 96 | 22 |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 96 | 21 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 94 | 23 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 93 | 24 |
| Fluoxetine Hcl | Fluoxetine Hcl | 93 | 26 |
| Lorazepam | Lorazepam | 93 | 14 |
| Fluconazole | Fluconazole | 92 | 49 |
| Celecoxib | Celecoxib | 87 | 21 |
| Methocarbamol | Methocarbamol | 87 | 31 |
| Prednisone | Prednisone | 86 | 51 |
| Paroxetine Hcl | Paroxetine Hcl | 83 | 22 |
| Linzess | Linaclotide | 81 | 16 |
| Liothyronine Sodium | Liothyronine Sodium | 81 | 15 |
| Clopidogrel | Clopidogrel Bisulfate | 80 | 25 |
| Spironolactone | Spironolactone | 80 | 23 |
| Ropinirole Hcl | Ropinirole Hcl | 78 | 17 |
| Glimepiride | Glimepiride | 77 | 24 |
| Simvastatin | Simvastatin | 77 | 21 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 75 | 21 |
| Donepezil Hcl | Donepezil Hcl | 71 | 13 |
| Zolpidem Tartrate | Zolpidem Tartrate | 70 | suppressed |
| Cefdinir | Cefdinir | 68 | 55 |
| Doxycycline Hyclate | Doxycycline Hyclate | 68 | 40 |
| Mirtazapine | Mirtazapine | 68 | 13 |
| Anastrozole | Anastrozole | 66 | 17 |
| Benazepril Hcl | Benazepril Hcl | 66 | 17 |
| Naproxen | Naproxen | 66 | 23 |
| Jardiance | Empagliflozin | 65 | 13 |
| Irbesartan | Irbesartan | 64 | 13 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 62 | 55 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 59 | 13 |
| Myrbetriq | Mirabegron | 58 | 12 |
| Nystatin | Nystatin | 58 | 24 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 57 | 13 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 56 | 17 |
| Hydralazine Hcl | Hydralazine Hcl | 54 | 14 |
| Ondansetron Hcl | Ondansetron Hcl | 53 | 25 |
| Synthroid | Levothyroxine Sodium | 53 | 11 |
| Atenolol | Atenolol | 52 | suppressed |
| Estradiol | Estradiol | 52 | suppressed |
| Ondansetron Odt | Ondansetron | 51 | 29 |
| Cephalexin | Cephalexin | 50 | 41 |
| Topiramate | Topiramate | 50 | 14 |
| Vascepa | Icosapent Ethyl | 50 | suppressed |
| Valsartan | Valsartan | 49 | 14 |
| Warfarin Sodium | Warfarin Sodium | 49 | suppressed |
| Azithromycin | Azithromycin | 48 | 42 |
| Tresiba Flextouch U-200 | Insulin Degludec | 48 | 11 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 47 | 26 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 46 | suppressed |
| Fenofibrate | Fenofibrate | 45 | 12 |
| Novolog Flexpen | Insulin Aspart | 45 | 11 |
| Rybelsus | Semaglutide | 45 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 43 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 42 | 20 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 41 | 11 |
| Primidone | Primidone | 41 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 40 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 40 | 11 |
| Promethazine Hcl | Promethazine Hcl | 40 | 11 |
| Ventolin Hfa | Albuterol Sulfate | 38 | suppressed |
| Baclofen | Baclofen | 37 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 37 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 37 | 12 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 36 | 11 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 36 | 30 |
| Fenofibrate | Fenofibrate Nanocrystallized | 36 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 36 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 36 | suppressed |
| Glipizide | Glipizide | 35 | suppressed |
| Lamotrigine | Lamotrigine | 35 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 35 | 15 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 35 | 16 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 34 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 33 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 33 | suppressed |
| Kerendia | Finerenone | 33 | suppressed |
| Memantine Hcl | Memantine Hcl | 33 | suppressed |
| Sucralfate | Sucralfate | 33 | 12 |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 32 | 12 |
| Finasteride | Finasteride | 31 | 11 |
| Risperidone | Risperidone | 31 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 31 | 11 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 30 | suppressed |
| Januvia | Sitagliptin Phosphate | 30 | suppressed |
| Levetiracetam | Levetiracetam | 30 | suppressed |
| Mupirocin | Mupirocin | 30 | 26 |
| Solifenacin Succinate | Solifenacin Succinate | 30 | suppressed |
| Torsemide | Torsemide | 30 | suppressed |
| Vraylar | Cariprazine Hcl | 30 | suppressed |
| Klor-Con M20 | Potassium Chloride | 29 | suppressed |
| Lansoprazole | Lansoprazole | 29 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 29 | suppressed |
| Aripiprazole | Aripiprazole | 28 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 26 | 11 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 26 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 26 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 24 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 24 | suppressed |
| Gemtesa | Vibegron | 24 | suppressed |
| Olanzapine | Olanzapine | 24 | suppressed |
| Repatha Sureclick | Evolocumab | 24 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 23 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 23 | 23 |
| Modafinil | Modafinil | 22 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 22 | suppressed |
| Otezla | Apremilast | 21 | suppressed |
| Trulicity | Dulaglutide | 21 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 20 | suppressed |
| Ibuprofen | Ibuprofen | 20 | suppressed |
| Nitroglycerin | Nitroglycerin | 20 | suppressed |
| Roflumilast | Roflumilast | 20 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 20 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 19 | 16 |
| Propranolol Hcl | Propranolol Hcl | 19 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 18 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 18 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 18 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 18 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 17 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 16 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 16 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 16 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 16 | suppressed |
| Lactulose | Lactulose | 16 | suppressed |
| Lovastatin | Lovastatin | 16 | suppressed |
| Verapamil Sr | Verapamil Hcl | 16 | suppressed |
| Invokana | Canagliflozin | 15 | suppressed |
| Nifedipine Er | Nifedipine | 15 | suppressed |
| Acyclovir | Acyclovir | 14 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 14 | suppressed |
| Colchicine | Colchicine | 14 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Procto-Med Hc | Hydrocortisone | 14 | suppressed |
| Ramipril | Ramipril | 14 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 14 | suppressed |
| Xarelto | Rivaroxaban | 14 | suppressed |
| Belsomra | Suvorexant | 13 | suppressed |
| Carbamazepine Er | Carbamazepine | 13 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 13 | suppressed |
| Fluoxetine Dr | Fluoxetine Hcl | 13 | suppressed |
| Jentadueto | Linagliptin/Metformin Hcl | 13 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 13 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Verapamil Er | Verapamil Hcl | 13 | suppressed |
| Cetirizine Hcl | Cetirizine Hcl | 12 | suppressed |
| Chlorthalidone | Chlorthalidone | 12 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 12 | suppressed |
| Ibu | Ibuprofen | 12 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 12 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 12 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 11 | suppressed |
| Bevespi Aerosphere | Glycopyrrolate/Formoterol Fum | 11 | suppressed |
| Estradiol (Once Weekly) | Estradiol | 11 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 11 | suppressed |
| Insulin Lispro | Insulin Lispro | 11 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 11 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 11 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 11 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 11 | suppressed |
| Techlite Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Tradjenta | Linagliptin | 11 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $984.03 · 45 records | Axsome Therapeutics, Inc. | ABRYSVO, ACCRUFER, Auvelity, CAPLYTA, COMIRNATY, ELIQUIS, FARXIGA, GEMTESA, GVOKE HYPOPEN, INSPIRE, JARDIANCE, Kerendia, MOUNJARO, NEXLETOL, NURTEC ODT, Ozempic, PREVNAR 20, REPATHA, Rybelsus, TRELEGY ELLIPTA, VRAYLAR, Wegovy, XIFAXAN, ZEPBOUND | 16 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error